Last update Jan. 15, 2023

Pramipexole Hydrochloride

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

It is a non-ergot dopamine agonist with bromocriptine-like actions that is used to treat the signs and symptoms of idiopathic Parkinson's disease and restless legs syndrome. Oral administration three times a day.

At the date of the last update we did not find any published data on its excretion in breast milk.

It decreases prolactin levels (Kelleher 2012), so milk production may decrease during the first weeks after delivery. When lactation is well established, milk production is not as dependent on prolactin levels. (Messinis 1985)

May cause severe drowsiness. (Hauser 2000)

Alternatives

We do not have alternatives for Pramipexole Hydrochloride.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Pramipexole Hydrochloride in other languages or writings:

Group

Pramipexole Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Pramipexole Hydrochloride in its composition:

List of 21 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 95 %
Molecular weight 302 daltons
Protein Binding 15 %
VD 7.1 l/Kg
pKa 17.6 -
Tmax 2 (1 - 3) hours
T½ 8.5 - 12 hours

References

  1. Boehringer I. Pramipexole. Drug Summary. 2020 Full text (in our servers)
  2. EMA. Pramipexol. Ficha técnica. 2013 Full text (in our servers)
  3. Kelleher JP, Centorrino F, Huxley NA, Bates JA, Drake JK, Egli S, Baldessarini RJ. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol. 2012 Jun;22(6):415-8. Abstract
  4. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord. 2000 Jul;15(4):658-63. Abstract
  5. Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Invest. 1985 Apr;8(2):143-6. Abstract

Total visits

5,840

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM